Triptan persistency among newly initiated users in a pharmacy claims database

Cephalalgia

Volumn 31, Issue 4, 2011, Pages 488-500

  Katić, Božena J ^a   Rajagopalan, Srini ^b   Ho, Tony W ^a   Chen, Ya Ting ^a   Hu, X Henry ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Med Data Analytics ^*  (United States)

Author keywords

claims data; migraine medication adherence; refill patterns; Triptan persistency

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; BUTALBITAL; CAFFEINE; CODEINE; DEXTROPROPOXYPHENE; DICLOFENAC; ELETRIPTAN; ERGOTAMINE; FROVATRIPTAN; HYDROCODONE BITARTRATE; IBUPROFEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN; TRYPTAMINE DERIVATIVE;

ADULT; ARTICLE; DATA BASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MONOTHERAPY; PRESCRIPTION; REIMBURSEMENT; UNITED STATES; COHORT ANALYSIS; COMPARATIVE STUDY; FACTUAL DATABASE; INSURANCE; MIDDLE AGED; PHARMACY; RETROSPECTIVE STUDY;

ADULT; COHORT STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PHARMACY; RETROSPECTIVE STUDIES; TRYPTAMINES; YOUNG ADULT;

EID: 84862833181     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410383058     Document Type: Article

References (36)

1. Lipton RB, Stewart WF, Diamond S., Diamond ML and Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 ; 41: 646-657. (Pubitemid 32777747)
2. Malik SN, Hopkins M., Young WB and Silberstein SD Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache 2006 ; 46: 773-780.
3. Hazard E., Munakata J., Bigal ME, Rupnow MF and Lipton RB The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health 2009 ; 12: 55.
4. Diamond S., Bigal ME, Silberstein S., Loder E., Reed M. and Lipton RB Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2006 ; 0: 355-363. (Pubitemid 46426410)
5. Lipton RB, Amatniek JC, Ferrari MD and Gross M. Migraine. Identifying and removing barriers to care. Neurology 1994 ; 44.
6. Silberstein SD, Dodick D. and Kesslick J. Removing barriers to appropriate migraine treatment: formulary limitations and triptan package size. Headache 2005 ; 45: 1250-1254. (Pubitemid 350004916)
7. Wenzel R., Dortch M., Cady R., Lofland JH and Diamond S. Migraine headache misconceptions: barriers to effective care. Pharmacotherapy 2004 ; 24: 638-648. (Pubitemid 38585958)
8. Snow V. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002 ; 137: 840-849. (Pubitemid 35334454)
9. Evers S., Afra J., Frese A., et al. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol 2006 ; 13: 560-572. (Pubitemid 43873628)
10. Demarin V., Vuković V., Huzjan A., et al. [Evidence based guidelines for the treatment of primary headaches.] [Croatian.]. Acta Med Croatica 2008 ; 62: 99-136.
11. Savani N., Martin A. and Browning D. Switching patients with migraine from sumatriptan to other triptans increases primary care costs. Int J Clin Pract 2004 ; 58: 758-763. (Pubitemid 39232320)
12. Pavone E., Banfi R., Vaiani M. and Panconesi A. Patterns of triptans use: a study based on the records of a community pharmaceutical department. Cephalalgia 2007 ; 27: 1000-1004. (Pubitemid 47296034)
13. Ifergane G., Wirguin I. and Shvartzman P. Triptans-why once? Headache 2006 ; 46: 1261-1263.
14. Panconesi A., Pavone E., Franchini M., et al. Triptans: low utilization and high turnover in the general population. Cephalalgia 2009 ; 30 (5). 576-581.
15. Lohman JJ and van der Kuy-de Ree MM. Patterns of specific antimigraine drug use-a study based on the records of 18 community pharmacies. Cephalalgia 2005 ; 25: 214-218. (Pubitemid 40321714)
16. Rahimtoola H., Buurma H., Tijssen CC, Leufkens HG and Egberts AC Single use of sumatriptan: a patient interview study. Headache 2003 ; 43: 109-116. (Pubitemid 36188440)
17. Etemad LR, Yang W., Globe D., Barlev A. and Johnson KA Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm 2005 ; 11: 137-144.
18. Yaldo AZ, Wertz DA, Rupnow MF and Quimbo RM Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting. Clin Ther 2008 ; 30: 2452-2460.
19. Cramer JA, Roy A., Burrell A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008 ; 11: 44-47. (Pubitemid 351160875)
20. Menckeberg TT, Belitser SV, Bouvy ML, et al. Distinguishing patterns in the dynamics of long-term medication use by Markov analysis: beyond persistence. BMC Health Serv Res 2007 ; 7: 106.
21. Girard P., Blaschke TF, Kastrissios H. and Sheiner LB A Markov mixed effect regression model for drug compliance. Stat Med 1998 ; 17: 2313-2333. (Pubitemid 28482676)
22. Bigal ME, Borucho S., Serrano D. and Lipton RB The acute treatment of episodic and chronic migraine in the USA. Cephalalgia 2009 ; 29: 891-897.
23. Buse DC, Manack A., Serrano D., Turkel C. and Lipton RB Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010 ; 81: 428-432.
24. Diener HC, Küper M. and Kurth T. Migraine-associated risks and comorbidity. J Neurol 2008 ; 255: 1290-1301.
25. Kurth T. Associations between migraine and cardiovascular disease. Expert Rev Neurother 2007 ; 7: 1097-1104. (Pubitemid 47451017)
26. Bigal ME, Liberman JN and Lipton RB Obesity and migraine: a population study. Neurology 2006 ; 66: 545-550. (Pubitemid 43739885)
27. Aamodt AH, Stovner LJ, Hagen K. and Zwart JA Comorbidity of headache and gastrointestinal complaints. The Head-HUNT Study. Cephalalgia 2008 ; 28: 144-151.
28. Sevillano-Garcia MD, Manso-Calderón R. and Cacabelos-Perez P. [Comorbidity in the migraine: depression, anxiety, stress and insomnia.] [Spanish.]. Rev Neurol 2007 ; 45: 400-405. (Pubitemid 350292916)
29. Katić BJ, Golden W., Cady RK and Hu XH GERD prevalence in migraine patients and the implication for acute migraine treatment. J Headache Pain 2009 ; 10: 35-43.
30. Merikangas KR, Fenton BT, Cheng SH, Stolar MJ and Risch N. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 1997 ; 54: 362-368. (Pubitemid 27172854)
31. Dodick DW, Martin VT, Smith T. and Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004 ; 44.
32. Bickel A., Kornhuber J., Maihofner C. and Ropohl A. Exacerbation of migraine attacks during treatment with the selective serotonin reuptake inhibitor sertraline. A case report. Pharmacopsychiatry 2005 ; 38: 327-328. (Pubitemid 41815692)
33. Bigal ME and Lipton RB Excessive opioid use and the development of chronic migraine. Pain 2009 ; 142: 179-182.
34. Bigal ME and Lipton RB Excessive acute migraine medication use and migraine progression. Neurology 2008 ; 71: 1821-1828.
35. Bigal ME, Serrano D., Reed M. and Lipton RB Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008 ; 71: 559-566.
36. Ho TW, Rodgers A. and Bigal ME Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache 2009 ; 49: 395-403.